WO2024049226A1 - Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif - Google Patents

Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif Download PDF

Info

Publication number
WO2024049226A1
WO2024049226A1 PCT/KR2023/012951 KR2023012951W WO2024049226A1 WO 2024049226 A1 WO2024049226 A1 WO 2024049226A1 KR 2023012951 W KR2023012951 W KR 2023012951W WO 2024049226 A1 WO2024049226 A1 WO 2024049226A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
cosmetic composition
preventing
active ingredient
lotion
Prior art date
Application number
PCT/KR2023/012951
Other languages
English (en)
Korean (ko)
Inventor
이애영
진영원
김하정
김난형
Original Assignee
동국대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020230112872A external-priority patent/KR20240031905A/ko
Application filed by 동국대학교 산학협력단 filed Critical 동국대학교 산학협력단
Publication of WO2024049226A1 publication Critical patent/WO2024049226A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a cosmetic composition for preventing or improving skin diseases containing a compound derived from Tribulus terrestris as an active ingredient.
  • Aging is a phenomenon in which an organism's physical functions deteriorate over time.
  • Cellular aging occurs when cells lose their ability to divide.
  • cellular aging includes aging mechanisms dependent on the Rb (retinoblastoma) protein, aging caused by loss of telomeres that protect chromosomes, aging caused by antioxidant stress, and aging caused by DNA damage.
  • Rb retinoblastoma
  • skin aging is divided into intrinsic aging (intrinsic aging) and extrinsic aging (extrinsic aging).
  • Endogenous aging is a phenomenon that occurs naturally over time due to the influence of genetic factors, regardless of the external environment. It is difficult to control artificially, and functional changes occur rather than visual or morphological changes.
  • extrinsic aging is a phenomenon caused by external environmental factors such as chronic exposure to sunlight, and is relatively easy to artificially control, and structural and physiological changes occur clearly. Because it is mainly caused by exposure to sunlight (ultraviolet rays), it is also called photoaging. In aged skin, increased drug penetration, increased susceptibility to irritant contact dermatitis, worsening skin dryness, itching, wrinkles, and pigment abnormalities (age spots, freckles, etc.) occur.
  • melanin the quinone complex called melanin, which is synthesized by melanin-forming cells present in the basal cell layer of the epidermis, plays the most important role.
  • melanin not only determines a person's skin color but also plays a role in protecting the skin. However, if it is produced excessively within the skin, pigmentation occurs within the skin, causing the skin to darken, spots, and freckles to appear.
  • the cause of melanin production is a combination of external environmental changes such as exposure to ultraviolet rays, air pollutants, medications, irritating skin external agents, and stress, as well as internal factors such as hormonal imbalance, inflammatory response factors, and cytokines, but the most important factor among them is melanin production. It is exposure to ultraviolet rays.
  • tyrosinase enzyme plays a critical role in melanin synthesis
  • methods of reducing melanin production by mixing substances with an inhibitory effect on tyrosinase activity into cosmetics or inhibiting some reactions during the melanin production process have been developed. It is commonly used.
  • Representative materials that inhibit tyrosinase activity include hydroquinone, azelaic acid, and kojic acid, and a combination of hydroquinone + tretinoin + steroid is also used in the form of an external preparation, but the effect is not yet satisfactory. It's not a bad situation.
  • the purpose of the present invention is to provide a cosmetic composition for preventing or improving skin diseases containing a compound derived from Tribulus terrestris as an active ingredient.
  • Another object of the present invention is to provide a health functional food composition for preventing or improving skin diseases containing the above compound as an active ingredient.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin diseases containing the above compound as an active ingredient.
  • the present invention provides a cosmetic composition for preventing or improving skin diseases containing a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a health functional food composition for preventing or improving skin diseases containing the above compound or a foodologically acceptable salt thereof as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases comprising the above compound or a pharmaceutically acceptable salt thereof as an active ingredient.
  • a specific compound derived from a Tribulus terrestris fraction simultaneously exhibits anti-aging and whitening effects, it can be usefully used as a composition for preventing, treating or improving skin diseases.
  • Figure 1 shows the results of analyzing the cytotoxicity of T13 compound, a compound derived from Tribulus terrestris fraction, in melanocytes.
  • Figure 2 shows the results of analyzing the effect of the T13 compound on tyrosinase expression in melanocytes.
  • Figure 3 shows the results of analyzing the effect of the T13 compound on tyrosinase expression in the three cell models produced in Example 2-1.
  • Figure 4 shows the results of analyzing the effect of T13 compound on p16 (Ink4a) expression in keratinocytes.
  • the present invention provides a cosmetic composition for preventing or improving skin diseases comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the compound or a pharmaceutically acceptable salt thereof may be derived from Tribulus terrestris .
  • the pharmaceutically acceptable salt of the compound may exhibit anti-aging or whitening effects and may inhibit p16 (Ink4a) or tyrosinase expression.
  • the skin disease includes skin aging disease; Alternatively, it may be a skin disease caused by excessive melanin production.
  • the skin aging disease may be one or more selected from the group consisting of skin wrinkles, photoaging, melanosis, skin pigmentation, skin burns, skin inflammation, and skin cancer, and the skin disease caused by excessive melanin production may include spots, freckles, blemishes, It may be one or more selected from the group consisting of age spots and nevus of Ota, but is not limited thereto.
  • the “whitening” refers to the action of suppressing, inhibiting, or alleviating excessive deposition of melanin pigment, etc., preventing darkening of the skin caused by the pigmentation, and improving skin troubles.
  • cosmetics may include functional cosmetics that have effects such as improving skin diseases, and the functional cosmetics, unlike general cosmetics, have specialized functionality that emphasizes bioactive effects and effects, as defined in the Cosmetics Act. Accordingly, it refers to cosmetics that emphasize specific efficacy and effects, such as improving skin diseases.
  • the term “including as an active ingredient” may mean containing an effective amount that can show an effect of improving skin diseases.
  • the cosmetic composition can be prepared in a general emulsified formulation and solubilized formulation.
  • lotion such as softening lotion or nourishing lotion
  • Emulsions such as facial lotion and body lotion
  • Creams such as nutritional cream, moisture cream, eye cream, etc.; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; Foundation, such as liquid type, solid type, or spray type; powder
  • Make-up removers such as cleansing creams, cleansing lotions, and cleansing oils
  • it may be formulated as a cleansing agent such as cleansing foam, soap, or body wash, but is not limited to this.
  • the skin external preparation may be formulated as an ointment, patch, gel, cream, or spray, but is not limited thereto.
  • the cosmetic composition may contain a generally acceptable carrier and may be appropriately mixed with, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, colorant, preservative, fragrance, etc., but is not limited thereto. no.
  • the acceptable carrier may vary depending on the formulation. For example, when formulated into ointments, pastes, creams or gels, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or these are used as carrier ingredients. Extracts may be used.
  • the cosmetic composition When the cosmetic composition is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, or extracts thereof may be used as carrier ingredients, and in the case of a spray, chlorofluorohydride may be used. It may further contain propellants such as carbon, propane, butane or dimethyl ether.
  • a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-Butylglycol oil may be used, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
  • the carrier component When the cosmetic composition is formulated as a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
  • a liquid diluent such as ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
  • alkali metal salts of fatty acids fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. are used as carrier ingredients.
  • alkali metal salts of fatty acids fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc.
  • fatty acids fatty acid hemiester salts
  • fatty acid protein hydrolyzates isethionates
  • lanolin derivatives fatty alcohols
  • vegetable oils glycerol, sugars, etc.
  • the cosmetic composition may contain fatty substances, organic solvents, solubilizers, thickeners, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, and fragrances commonly used in the industry depending on the quality or function of the final product. , surfactants, water, ionic or non-ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activators, commonly used in cosmetics. It may additionally contain auxiliaries commonly used in the fields of cosmetology or dermatology, such as any other ingredients.
  • auxiliaries and their mixing ratio may be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.
  • the present invention provides a health functional food composition for preventing or improving skin diseases containing a compound represented by the following formula (1) or a foodologically acceptable salt thereof as an active ingredient.
  • the present invention can be generally used with commonly used foods.
  • the food composition of the present invention can be used as a health functional food.
  • health functional food refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with the Health Functional Food Act, and “functionality” refers to food that is related to the structure and function of the human body. It means ingestion for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects.
  • the health functional food composition may contain common food additives, and its suitability as a “food additive” is determined in accordance with the general provisions and general test methods of the food additive code approved by the Ministry of Food and Drug Safety, unless otherwise specified. The decision is made based on the specifications and standards for the item.
  • Items listed in the “Food Additives Code” include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as subchromic pigment, licorice extract, crystalline cellulose, high-liquid pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations.
  • the food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc.
  • hard capsules can be manufactured by mixing and filling the composition according to the present invention with additives such as excipients in a regular hard capsule
  • soft capsules can be manufactured by mixing and filling the composition according to the present invention. It can be manufactured by mixing with additives such as excipients and filling it with a capsule base such as gelatin.
  • the soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary.
  • prevention refers to all actions that suppress or delay skin disease by administering the composition according to the present invention.
  • treatment refers to any action that improves or beneficially changes the symptoms of a skin disease by administering the composition according to the present invention.
  • the term “improvement” refers to any action that improves the bad condition of a skin disease by administering the composition according to the present invention.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the pharmaceutical composition of the present invention is prepared in unit dose form or in a multi-dose container by formulating it using a pharmaceutically acceptable carrier according to a method that can be easily performed by a person skilled in the art. It can be manufactured by internalizing it.
  • the pharmaceutically acceptable carriers are those commonly used in preparation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Includes, but is not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc.
  • the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.
  • the content of additives included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.
  • the pharmaceutical compositions include injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, tablets, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, paste agents, and cataplasmase agents. It may be formulated in the form of one or more external skin preparations selected from the group consisting of, but is not limited to this.
  • the pharmaceutical composition of the present invention may additionally contain pharmaceutically acceptable carriers and diluents for formulation.
  • the pharmaceutically acceptable carriers and diluents include excipients such as starch, sugar and mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethylcellulose, hydroxypropylcellulose, gelatin, alginate, polyvinyl pyrrolidone. It includes, but is not limited to, binders such as talc, calcium stearate, lubricants such as hydrogenated castor oil and polyethylene glycol, disintegrants such as povidone and crospovidone, and surfactants such as polysorbate, cetyl alcohol, glycerol, etc.
  • the pharmaceutically acceptable carrier and diluent may be biologically and physiologically friendly to the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents, and/or dispersion media.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally, or topically) depending on the desired method.
  • parenterally for example, intravenously, subcutaneously, intraperitoneally, or topically
  • it can be formulated as tablets, troches, lozenges, aqueous suspensions, oily suspensions, powders, granules, emulsions, hard capsules, soft capsules, syrups, elixirs, etc.
  • parenteral administration it can be formulated as an injection, suppository, powder for respiratory inhalation, aerosol for spray, ointment, powder for application, oil, cream, etc.
  • the dosage of the pharmaceutical composition of the present invention is determined by the patient's condition, weight, age, gender, health, dietary constitution specificity, nature of the preparation, degree of disease, administration time of the composition, administration method, administration period or interval, excretion rate, and
  • the range may vary depending on the drug form and can be appropriately selected by a person skilled in the art. For example, it may range from about 0.1 to 10,000 mg/kg, but is not limited and may be administered once to several times a day.
  • the pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally, or topically applied) depending on the desired method.
  • the pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time, administration route, etc. of the pharmaceutical composition, and those skilled in the art will know that it is effective for the desired treatment. Dosage can be easily determined and prescribed.
  • the pharmaceutical composition of the present invention may be administered once a day, or may be administered in several divided doses.
  • Keratinocytes were isolated and used from normal adult skin tissue obtained through repeated cesarean section and circumcision. The cells were dispensed in EpiLife Medium, and bovine pituitary extract (BPE), bovine insulin (BI), hydrocortisone, human epidermal growth factor (EGF), and bovine transferrin ( Bovine transferrin (BT) was added and cultured. Cells subcultured 3 to 5 times were used in the experiment.
  • BPE bovine pituitary extract
  • BI bovine insulin
  • hydrocortisone human epidermal growth factor
  • bovine transferrin Bovine transferrin
  • BPE bovine pituitary extract
  • FBS fetal bovine serum
  • bFGF basic fibroblast growth factor
  • BT bovine transferrin
  • PMA phorbol 12-myristate13-acetate
  • MTT assay was performed. After treating melanocytes with each of the candidate materials at each concentration (10, 50, and 100 ⁇ M) for 48 hours, cell viability was measured to confirm the concentration range in which each candidate material does not exhibit cytotoxicity.
  • Example 1-2 Western blot was performed. After treating melanocytes with each of the candidate materials identified in Example 1-2 at a concentration that does not show cytotoxicity to melanocytes for 48 hours, intracellular tyrosinase expression was measured. The experiment was repeated more than four times.
  • tyrosinase expression was significantly reduced in the 16 types of candidate material treatment groups, and as shown in Figure 2, among them, tyrosinase in the T13 compound treatment group (10 ⁇ M) compared to the control group (CON; candidate material untreated group) Expression was significantly decreased.
  • Example 1-2 In order to identify substances that exhibit both skin whitening and anti-aging effects among the 16 candidate materials in Example 1-2, three types of cell models were first produced as follows.
  • Keratinocytes were seeded in a culture vessel at 2 ⁇ 10 5 /ml, and after 24 hours, three genes [ARG2 (Arginase 2, NCBI Gene ID: 384), CDH11 (Cadherin 11, NCBI Gene: 1009) and GDA (guanine deaminase, NCBI Gene: 9615)] was transfected into cells using Lipofectamine 2000 to induce overexpression, and then cultured in supplement-free DMEM (Dulbecco's Modified Essential). After culturing for 4 hours in Medium) culture medium, 0.5 ⁇ 10 5 /ml melanocytes were mixed with keratinocyte culture medium containing supplement and co-cultured in the same culture vessel.
  • ARG2 Arginase 2, NCBI Gene ID: 384
  • CDH11 CDH11
  • GDA guanine deaminase, NCBI Gene: 9615
  • a cell model in which keratinocytes overexpressing each of the three genes (ARG2, CDH11, and GDA) and normal melanocytes were co-cultured was set as a control, and keratinocytes overexpressing each of the three genes were It was prepared by transfecting keratinocytes with pCMV plasmid containing an empty vector without the above three genes.
  • the skin whitening effect was determined by applying each of the 16 types of candidate materials to the 3 types of cell models produced in Example 2-1. After treating the melanocytes identified in Example 1-1 at a concentration that does not show cytotoxicity for 48 hours, Western blot was performed to measure tyrosinase expression. The experiment was repeated 4 times, and P ⁇ 0.05 was considered significant. In addition, to analyze the anti-aging effect, keratinocytes were treated with each of the 16 candidate materials for 48 hours, and then Western blot was performed to measure p16 (Ink4a) expression. The experiment was repeated four times, and P ⁇ 0.05 was considered significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique destinée à prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de Tribulus terrestris en tant que principe actif. Il a été prouvé qu'un composé spécifique dérivé d'une fraction de Tribulus terrestris présente des effets anti-vieillissement et de blanchiment simultanément, et peut ainsi être efficacement utilisé en tant que composition pour prévenir, traiter ou atténuer des maladies de la peau.
PCT/KR2023/012951 2022-08-31 2023-08-31 Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif WO2024049226A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20220109615 2022-08-31
KR10-2022-0109615 2022-08-31
KR1020230112872A KR20240031905A (ko) 2022-08-31 2023-08-28 남가새 유래 화합물을 유효성분으로 포함하는 피부 질환 예방 또는 개선용 화장료 조성물
KR10-2023-0112872 2023-08-28

Publications (1)

Publication Number Publication Date
WO2024049226A1 true WO2024049226A1 (fr) 2024-03-07

Family

ID=90098374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/012951 WO2024049226A1 (fr) 2022-08-31 2023-08-31 Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif

Country Status (1)

Country Link
WO (1) WO2024049226A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03190809A (ja) * 1989-12-21 1991-08-20 Shiseido Co Ltd 肌荒れ防止改善剤
JP2002363088A (ja) * 2001-06-08 2002-12-18 Ichimaru Pharcos Co Ltd エラスターゼ活性阻害剤又は化粧料組成物
JP2005089376A (ja) * 2003-09-18 2005-04-07 Noevir Co Ltd 美白剤及び抗酸化剤
US20130310332A1 (en) * 2010-10-25 2013-11-21 University Of Rhode Island Maple tree-derived products and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03190809A (ja) * 1989-12-21 1991-08-20 Shiseido Co Ltd 肌荒れ防止改善剤
JP2002363088A (ja) * 2001-06-08 2002-12-18 Ichimaru Pharcos Co Ltd エラスターゼ活性阻害剤又は化粧料組成物
JP2005089376A (ja) * 2003-09-18 2005-04-07 Noevir Co Ltd 美白剤及び抗酸化剤
US20130310332A1 (en) * 2010-10-25 2013-11-21 University Of Rhode Island Maple tree-derived products and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKASHIMA, S. ; MATSUDA, H. ; ODA, Y. ; NAKAMURA, S. ; XU, F. ; YOSHIKAWA, M.: "Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 6, 15 March 2010 (2010-03-15), AMSTERDAM, NL, pages 2337 - 2345, XP026941365, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2010.01.046 *
ZHENG-QUN ZHOU, JIA XIAO, HONG-XIA FAN, YANG YU, RONG-RONG HE, XIAO-LIN FENG, HIROSHI KURIHARA, KWOK-FAI SO, XIN-SHENG YAO, HAO GA: "Polyphenols from wolfberry and their bioactivities", FOOD CHEMISTRY, ELSEVIER LTD., NL, vol. 214, 1 January 2017 (2017-01-01), NL , pages 644 - 654, XP055630221, ISSN: 0308-8146, DOI: 10.1016/j.foodchem.2016.07.105 *

Similar Documents

Publication Publication Date Title
WO2013027984A2 (fr) Composition cosmétique contenant un composant de thé vert
US8709511B2 (en) External preparation composition for skin comprising ginseng flower or ginseng seed extracts
US20100310485A1 (en) Use of melanin biosynthesis inhibitors from korean ginseng and the cosmetic composition containing thereof for skin whitening
CN111944870B (zh) 余甘子萃取发酵物及其制备与应用
WO2010079978A2 (fr) Composition utilisable pour le traitement de l'inflammation faisant appel à des antigènes abh
WO2020218888A1 (fr) Composition cosmétique pour le blanchiment de la peau contenant de nouvelles lactobacillus rhamnosus lm1011 en tant que principe actif
WO2017217695A1 (fr) Composition comprenant l'alpha-garcinia mangostana, le bêta-garcinia mangostana, le gamma-garcinia mangostana, ou le composé gartanin utilisé comme ingrédient efficace pour atténuer les rides de la peau ou pour hydrater la peau
KR102373899B1 (ko) 피부의 주름 개선, 미백, 세포 재생, 상처 치유에 유효한 복합 천연물 추출물을 활성성분으로 함유하는 다 기능성 화장품 조성물
WO2022015055A1 (fr) Composition pour prévenir la chute des cheveux et stimuler la pousse des cheveux
WO2024049226A1 (fr) Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif
WO2024049229A1 (fr) Composition cosmétique pour prévenir ou améliorer des maladies de la peau, comprenant un composé dérivé de morus alba en tant que principe actif
WO2021096089A1 (fr) Nouvelle composition comprenant des exosomes dérivés de cellules souches et du polydésoxyribonucléotide en tant que principes actifs
KR20140131243A (ko) 진세노사이드 ｆ2를 포함하는 탈모방지 또는 발모촉진용 조성물
CN117547524A (zh) 吉马酮化合物的新用途
WO2022240243A1 (fr) Composition de blanchiment de la peau contenant des nanovésicules
WO2021241780A1 (fr) Composition destinée à inhiber le grisonnement des cheveux, et son utilisation
KR20240031905A (ko) 남가새 유래 화합물을 유효성분으로 포함하는 피부 질환 예방 또는 개선용 화장료 조성물
KR101151007B1 (ko) 루시놀 및 니아신아마이드를 포함하는 피부 미백용 화장료 조성물
WO2020067663A1 (fr) Composition favorisant le renouvellement cellulaire et l'excrétion mélanique
WO2018004171A1 (fr) Composition visant à stimuler la différenciation des adipocytes et procédé de recherche par criblage de substances visant à stimuler la différenciation des adipocytes
WO2011136561A2 (fr) Composition pour le traitement du vitiligo contenant de la sérotonine comme principe actif
WO2022255799A1 (fr) Composition destinée à prévenir la chute des cheveux et à stimuler la pousse des cheveux, contenant gypsophila paniculata l.
WO2023018316A1 (fr) Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau
WO2023249305A1 (fr) Composition pour l'amélioration des rides de la peau, l'amélioration de la texture de la peau ou le blanchiment contenant un rétinoïde et un renforçateur de rétinoïde
WO2024167309A1 (fr) Composition pour améliorer l'état de la peau et la santé comprenant comme ingrédient principal une composition de principe actif contenant un mélange de coumestrol et d'isoflavone aglycone comme ingrédient principal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23860902

Country of ref document: EP

Kind code of ref document: A1